BioSpace News Archive

Bio-Techne Corporation was pleased to host presentations by three industry experts yesterday at the CASSS CE Pharm conference in Philadelphia, PA. These industry experts highlighted how Bio-Techne’s ProteinSimple branded Maurice™ and MauriceFlex™ systems improved their therapeutic development workflows.

Cidara Therapeutics, Inc. today announced that it will present new data on its drug-Fc conjugate (DFC) candidate, CD388, in an oral presentation and two poster presentations at IDWeek 2023.

Vaccinex, Inc today announced that it will present data on a new ActivMAb® application on September 28th and an update on the Phase 1b/2 pepinemab study in patients with PDAC on September 29th.

Verrica Pharmaceuticals Inc. today announced that it will host a virtual KOL event discussing the approval of YCANTH™ (cantharidin) topical solution for the treatment of molluscum contagiosum on Wednesday, October 11, 2023 at 11:00 AM ET. To register, click here.

Femasys Inc. today announced that it has activated enrollment for its pivotal FemBloc trial at its first academic site located in Brooklyn, New York.

Flamingo Therapeutics (“Flamingo”) today announced that company management will participate at several upcoming investor and industry conferences in October 2023.

BioProtect Ltd, a private Med Tech company focused on providing innovative, biodegradable spacing solutions, announced today the successful close of a $28 million funding.

Seelos Therapeutics, Inc. today announced encouraging preclinical data from an in vivo study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) in an aggressive Alzheimer’s disease non-human primate model.

Edgewise Therapeutics, Inc. today announced that the Company will present on EDG-5506, an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, at the 28th International Annual Congress of the World Muscle Society (WMS).

Shionogi & Co., Ltd. announced the U.S. Food and Drug Administration (FDA) has granted Tetra Therapeutics Inc. (hereafter “Tetra”), a Shionogi Group Company, Rare Pediatric Disease Designation for zatolmilast (BPN14770), an investigational treatment being studied for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism.